International Journal of Nanomedicine,
Journal Year:
2021,
Volume and Issue:
Volume 16, P. 7891 - 7941
Published: Dec. 1, 2021
Abstract:
Despite
recent
advances
in
the
diagnosis
and
treatment
of
breast
cancer
(BC),
it
remains
a
global
health
issue
affecting
millions
women
annually.
Poor
prognosis
BC
patients
is
often
linked
to
drug
resistance
as
well
lack
effective
therapeutic
options
for
metastatic
triple-negative
BC.
In
response
these
unmet
needs,
extensive
research
efforts
have
been
devoted
exploring
anti-BC
potentials
natural
products
owing
their
multi-target
mechanisms
action
good
safety
profiles.
Various
medicinal
plant
extracts/essential
oils
bioactive
compounds
demonstrated
anti-cancer
activities
preclinical
models.
promising
results,
however,
clinical
translation
has
hindered
by
poor
stability,
aqueous
solubility
bioavailability.
There
attempts
overcome
limitations,
particularly
via
use
nano-based
delivery
systems
(NDDSs).
This
review
highlights
tumour
targeting
NDDSs,
advantages
disadvantages
major
classes
NDDSs
current
status
treatment.
Besides,
also
discusses
proposed
nanoformulations
nine
plants'
compounds;
selected
screening
various
scientific
databases,
including
PubMed,
Scopus
Google
Scholar,
based
on
following
keywords:
"Natural
Product
AND
Nanoparticle
Breast
Cancer".
Overall,
exhibit
improved
efficacy
against
models,
with
some
demonstrating
biocompatibility
normal
cell
lines
mouse
Further
studies
are,
warranted
ascertain
humans.
Keywords:
cancer,
delivery,
molecular
mechanisms,
nanoparticles,
products,
phytomedicine
Journal of Nanobiotechnology,
Journal Year:
2018,
Volume and Issue:
16(1)
Published: Sept. 19, 2018
Nanomedicine
and
nano
delivery
systems
are
a
relatively
new
but
rapidly
developing
science
where
materials
in
the
nanoscale
range
employed
to
serve
as
means
of
diagnostic
tools
or
deliver
therapeutic
agents
specific
targeted
sites
controlled
manner.
Nanotechnology
offers
multiple
benefits
treating
chronic
human
diseases
by
site-specific,
target-oriented
precise
medicines.
Recently,
there
number
outstanding
applications
nanomedicine
(chemotherapeutic
agents,
biological
immunotherapeutic
etc.)
treatment
various
diseases.
The
current
review,
presents
an
updated
summary
recent
advances
field
nanomedicines
based
drug
through
comprehensive
scrutiny
discovery
application
nanomaterials
improving
both
efficacy
novel
old
drugs
(e.g.,
natural
products)
selective
diagnosis
disease
marker
molecules.
opportunities
challenges
from
synthetic/natural
sources
their
clinical
also
discussed.
In
addition,
we
have
included
information
regarding
trends
perspectives
area.
Biotechnology Advances,
Journal Year:
2015,
Volume and Issue:
33(8), P. 1582 - 1614
Published: Aug. 15, 2015
Medicinal
plants
have
historically
proven
their
value
as
a
source
of
molecules
with
therapeutic
potential,
and
nowadays
still
represent
an
important
pool
for
the
identification
novel
drug
leads.
In
past
decades,
pharmaceutical
industry
focused
mainly
on
libraries
synthetic
compounds
discovery
source.
They
are
comparably
easy
to
produce
resupply,
demonstrate
good
compatibility
established
high
throughput
screening
(HTS)
platforms.
However,
at
same
time
there
has
been
declining
trend
in
number
new
drugs
reaching
market,
raising
renewed
scientific
interest
from
natural
sources,
despite
its
known
challenges.
this
survey,
brief
outline
historical
development
is
provided
together
comprehensive
overview
used
approaches
recent
developments
relevant
plant-derived
product
discovery.
Associated
challenges
major
strengths
product-based
critically
discussed.
A
snapshot
advanced
products
that
currently
actively
recruiting
clinical
trials
also
presented.
Importantly,
transition
compound
“screening
hit”
through
“drug
lead”
“marketed
drug”
associated
increasingly
challenging
demands
amount,
which
often
cannot
be
met
by
re-isolation
respective
plant
sources.
regard,
existing
alternatives
resupply
discussed,
including
different
biotechnology
total
organic
synthesis.
While
intrinsic
complexity
necessitates
highly
integrated
interdisciplinary
approaches,
reviewed
developments,
technological
advances,
research
trends
clearly
indicate
will
among
most
sources
future.
Advanced Healthcare Materials,
Journal Year:
2018,
Volume and Issue:
7(13)
Published: May 29, 2018
Abstract
The
increase
of
antibiotic
resistance
in
bacteria
has
become
a
major
concern
for
successful
diagnosis
and
treatment
infectious
diseases.
Over
the
past
few
decades,
significant
progress
been
achieved
on
development
nanotechnology‐based
medicines
combating
multidrug
microorganisms.
Among
this,
silver
nanoparticles
(AgNPs)
hold
great
promise
addressing
this
challenge
due
to
their
broad‐spectrum
robust
antimicrobial
properties.
This
review
illustrates
antibacterial
mechanisms
further
elucidates
how
different
structural
factors
including
surface
chemistry,
size,
shape,
impact
activities,
which
are
expected
promote
future
more
potent
nanoparticle‐based
agents.
Biochemical Pharmacology,
Journal Year:
2014,
Volume and Issue:
92(1), P. 73 - 89
Published: July 29, 2014
Agonists
of
the
nuclear
receptor
PPARγ
are
therapeutically
used
to
combat
hyperglycaemia
associated
with
metabolic
syndrome
and
type
2
diabetes.
In
spite
being
effective
in
normalization
blood
glucose
levels,
currently
agonists
from
thiazolidinedione
have
serious
side
effects,
making
discovery
novel
ligands
highly
relevant.
Natural
products
proven
historically
be
a
promising
pool
structures
for
drug
discovery,
significant
research
effort
has
recently
been
undertaken
explore
PPARγ-activating
potential
wide
range
natural
originating
traditionally
medicinal
plants
or
dietary
sources.
The
majority
identified
compounds
selective
modulators
(SPPARMs),
transactivating
expression
PPARγ-dependent
reporter
genes
as
partial
agonists.
Those
different
binding
modes
comparison
full
agonists,
on
some
occasions
activate
addition
PPARα
(e.g.
genistein,
biochanin
A,
sargaquinoic
acid,
sargahydroquinoic
resveratrol,
amorphastilbol)
PPARγ-dimer
partner
retinoid
X
(RXR;
e.g.
neolignans
magnolol
honokiol).
A
number
vivo
studies
suggest
that
product
activators
honokiol,
amorfrutin
1,
B,
improve
parameters
diabetic
animal
models,
partly
reduced
effects
bioactivity
pattern
well
use
several
active
plant
extracts
warrants
future
regarding
their
therapeutic
possibility
modulate
activation
by
interventions
food
supplements.
Marine Drugs,
Journal Year:
2014,
Volume and Issue:
12(2), P. 1066 - 1101
Published: Feb. 17, 2014
The
marine
environment
harbors
a
number
of
macro
and
micro
organisms
that
have
developed
unique
metabolic
abilities
to
ensure
their
survival
in
diverse
hostile
habitats,
resulting
the
biosynthesis
an
array
secondary
metabolites
with
specific
activities.
Several
these
are
high-value
commercial
products
for
pharmaceutical
cosmeceutical
industries.
aim
this
review
is
outline
paths
natural
discovery
development,
special
focus
on
compounds
successfully
reached
market
particularly
looking
at
approaches
tackled
by
cosmetic
companies
succeeded
marketing
those
products.
main
challenges
faced
during
bioactives
development
programs
were
analyzed
grouped
three
categories:
biodiversity
(accessibility
resources
efficient
screening),
supply
technical
(sustainable
production
knowledge
mechanism
action)
(processes,
costs,
partnerships
marketing).
Tips
surpass
given
order
improve
entry
success
rates
highly
promising
current
pipelines,
highlighting
what
can
be
learned
from
successful
unsuccessful
stories
applied
novel
and/or
ongoing
programs.
International Journal of Infectious Diseases,
Journal Year:
2011,
Volume and Issue:
15(8), P. e525 - e532
Published: May 26, 2011
About
1.5
million
new
cases
of
cutaneous
leishmaniasis
and
500,000
visceral
occur
each
year
around
the
world.
For
over
half
a
century,
clinical
forms
disease
have
been
treated
almost
exclusively
with
pentavalent
antimonial
compounds.
In
this
review,
we
describe
arsenal
available
for
treating
Leishmania
infections,
as
well
recent
advances
from
research
on
plants
synthetic
compounds
source
drugs
disease.
We
also
review
some
drug-delivery
systems
development
novel
chemotherapeutics.
observe
that
pharmaceutical
industry
should
employ
its
modern
technologies,
which
could
lead
to
better
use
their
extracts,
semi-synthetic
New
studies
highlighted
biopharmaceutical
technologies
in
design
delivery
strategy,
such
nanoparticles,
liposomes,
cochleates,
non-specific
lipid
transfer
proteins.
These
observations
serve
basis
indicate
routes
effective
anti-Leishmania
drugs.
Natural Product Research,
Journal Year:
2017,
Volume and Issue:
32(16), P. 1926 - 1950
Published: July 27, 2017
Natural
products
(NPs)
are
secondary
metabolites
produced
and
used
by
organisms
for
defending
or
adapting
purposes.
These
molecules
were
naturally
selected
during
thousands
of
years
to
improve
the
specificity
cover
a
very
wide
range
functions,
depending
on
origin,
habitat
specific
activity
carried
out
in
organism
origin.
Due
these
intrinsic
features,
NPs
have
been
as
healing
agents
since
still
today
continue
be
most
important
source
new
potential
therapeutic
preparations.The
purpose
this
review
is
provide
information
about
historical
evolution
investigation
methods,
focusing
attention
relative
benefit/problems
emerged
after
improvement
scientific
investigations
them,
especially
over
last
two
centuries.
Taken
together,
reported
lead
central
role
future
drug
development
human
needs.
Journal of Medicinal Chemistry,
Journal Year:
2015,
Volume and Issue:
59(5), P. 1671 - 1690
Published: Oct. 27, 2015
High-throughput
biology
has
contributed
a
wealth
of
data
on
chemicals,
including
natural
products
(NPs).
Recently,
attention
was
drawn
to
certain,
predominantly
synthetic,
compounds
that
are
responsible
for
disproportionate
percentages
hits
but
false
actives.
Spurious
bioassay
interference
led
their
designation
as
pan-assay
(PAINS).
NPs
lack
comparable
scrutiny,
which
this
study
aims
rectify.
Systematic
mining
80+
years
the
phytochemistry
and
literature,
using
NAPRALERT
database,
revealed
only
39
represent
most
reported
by
occurrence,
activity,
distinct
activity.
Over
50%
not
explained
phenomena
known
synthetic
libraries,
all
had
manifold
ascribed
bioactivities,
designating
them
invalid
metabolic
panaceas
(IMPs).
Cumulative
distributions
∼200,000
uncovered
NP
research
follows
power-law
characteristics
typical
behavioral
phenomena.
Projection
into
occurrence–bioactivity–effort
space
produces
hyperbolic
black
hole
NPs,
where
IMPs
populate
high-effort
base.